Baxdrostat

AstraZeneca · CIN-107 · RO6836191

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
7 active
26 in total · 9 in the EU
Targets
—
None known yet

What this is

How it works
Aldosterone synthase inhibitor
Tested for
Chronic Kidney Disease and Hypertension (3 trials), Primary Hyperaldosteronism, Uncontrolled Hypertension, Heart Failure
Main trialPhase 3
“Parent study: This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 250 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after…”In the company’s words, NCT07007793 on ClinicalTrials.gov
Other names
CIN-107 · RO6836191 · Baxfendy

Other drugs for Chronic Kidney Disease and Hypertension

All 79 drugs for Chronic Kidney Disease and Hypertension

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

FDA approvals1

Trials26

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 27 Jul 2027 Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
Phase 3Recruiting 9 Feb 2028 A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
Phase 3Active, not recruiting 24 Feb 2028 A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Phase 3Recruiting 17 Dec 2029 Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Phase 3Recruiting 18 Dec 2029 A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Phase 2Active, not recruiting 10 Dec 2026 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Phase 3Completed 21 May 2025 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 3Completed 17 Aug 2025 A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Phase 3Completed 24 Nov 2025 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 2Completed 14 Jun 2022 A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Phase 2Completed 13 Sep 2022 A Study of CIN-107 in Patients With Uncontrolled Hypertension
Phase 2Completed 7 Nov 2023 Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
Phase 2Completed 2 May 2024 A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Phase 2Completed 28 Oct 2024 A Study of CIN-107 in Adults With Primary Aldosteronism
Phase 2Completed 4 Dec 2024 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Phase 1Completed 3 Apr 2020 Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects
Phase 1Completed 29 Apr 2020 Baxdrostat Bioavailability and Bioequivalence Study
Phase 1Completed 12 Dec 2020 Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects
Phase 1Completed 30 Apr 2021 Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function
Phase 1Completed 15 Jan 2022 Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
Phase 1Completed 15 Apr 2022 Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment
Phase 1Completed 20 Sep 2022 Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
Phase 1Completed 13 May 2024 A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
Phase 1Completed 17 Jun 2024 A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants
Phase 1Completed 3 Feb 2025 A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
Phase 2Authorised not given A Proof of Concept, Single Arm, Open Label Study to Assess the Value of SBP response to Baxdrostat as a Discrimination Tool for Primary Aldosteronism in Newly Diagnosed Adults with Untreated Hypertension (BaxDetect)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Baxdrostat

Following is part of Solo: you see every change to Baxdrostat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in